Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience

Rolfes, L.; Pawlitzki, M.; Pfeuffer, S.; Nelke, C.; Lux, A.; Pul, R. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol. Neuroimmunol. Neuroinflamm., 2021, 8(5), e1035.
[http://dx.doi.org/10.1212/NXI.0000000000001035] [PMID: 34261812]

Bar-Or, A.; Calabresi, P.A.J.; Arnold, D.; Markowitz, C.; Shafer, S.; Kasper, L.H.; Waubant, E.; Gazda, S.; Fox, R.J.; Panzara, M.; Sarkar, N.; Agarwal, S.; Smith, C.H. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann. Neurol., 2008, 63(3), 395-400.
[http://dx.doi.org/10.1002/ana.21363] [PMID: 18383069]

D’Amico, E.; Zanghì, A.; Chisari, C.G.; Fermo, S.L.; Toscano, S.; Arena, S.; Patti, F.; Zappia, M. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Mult. Scler. Relat. Disord., 2019, 27, 324-326.
[http://dx.doi.org/10.1016/j.msard.2018.09.041] [PMID: 30471585]

Furlan, A.; Forner, G.; Cipriani, L.; Vian, E.; Rigoli, R.; Gherlinzoni, F.; Scotton, P. COVID-19 in B cell-depleted patients after rituximab: A diagnostic and therapeutic challenge. Front. Immunol., 2021, 12, 763412.
[http://dx.doi.org/10.3389/fimmu.2021.763412] [PMID: 34804051]

D’Amico, E.; Zanghì, A.; Gastaldi, M.; Patti, F.; Zappia, M.; Franciotta, D. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmun. Rev., 2019, 18(7), 665-672.
[http://dx.doi.org/10.1016/j.autrev.2019.05.003] [PMID: 31059839]

Schiavetti, I.; Ponzano, M.; Signori, A.; Bovis, F.; Carmisciano, L.; Sormani, M.P. Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis. Mult. Scler. Relat. Disord., 2022, 57, 103358.
[http://dx.doi.org/10.1016/j.msard.2021.103358] [PMID: 35158467]

Simpson-Yap, S.; De Brouwer, E.; Kalincik, T.; Rijke, N.; Hillert, J.A.; Walton, C.; Edan, G.; Moreau, Y.; Spelman, T.; Geys, L.; Parciak, T.; Gautrais, C.; Lazovski, N.; Pirmani, A.; Ardeshirdavanai, A.; Forsberg, L.; Glaser, A.; McBurney, R.; Schmidt, H.; Bergmann, A.B.; Braune, S.; Stahmann, A.; Middleton, R.; Salter, A.; Fox, R.J.; van der Walt, A.; Butzkueven, H.; Alroughani, R.; Ozakbas, S.; Rojas, J.I.; van der Mei, I.; Nag, N.; Ivanov, R.; Sciascia do Olival, G.; Dias, A.E.; Magyari, M.; Brum, D.; Mendes, M.F.; Alonso, R.N.; Nicholas, R.S.; Bauer, J.; Chertcoff, A.S.; Zabalza, A.; Arrambide, G.; Fidao, A.; Comi, G.; Peeters, L. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology, 2021, 97(19), e1870-e1885.
[http://dx.doi.org/10.1212/WNL.0000000000012753] [PMID: 34610987]

Sormani, M.P.; De Rossi, N.; Schiavetti, I.; Carmisciano, L.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; Trojano, M.; Zaratin, P.; Tedeschi, G.; Comi, G.; Battaglia, M.A.; Patti, F.; Salvetti, M.; Nozzolillo, A.; Bellacosa, A.; Protti, A.; Di Sapio, A.; Signori, A.; Petrone, A.; Bisecco, A.; Iovino, A.; Dutto, A.; Repice, A.M.; Conte, A.; Bertolotto, A.; Bosco, A.; Gallo, A.; Zito, A.; Sartori, A.; Giometto, B.; Tortorella, C.; Antozzi, C.; Pozzilli, C.; Mancinelli, C.R.; Zanetta, C.; Cordano, C.; Cordioli, C.; Scandellari, C.; Guaschino, C.; Gasperini, C.; Solaro, C.; Fioretti, C.; Bezzini, D.; Marastoni, D.; Paolicelli, D.; Vecchio, D.; Landi, D.; Bucciantini, E.; Pedrazzoli, E.; Signoriello, E.; Sbragia, E.; Susani, E.L.; Curti, E.; Milano, E.; Marinelli, F.; Camilli, F.; Boneschi, F.M.; Govone, F.; Bovis, F.; Calabria, F.; Caleri, F.; Rinaldi, F.; Vitetta, F.; Corea, F.; Crescenzo, F.; Patti, F.; Teatini, F.; Tabiadon, G.; Granella, F.; Boffa, G.; Lus, G.; Brichetto, G.; Comi, G.; Tedeschi, G.; Maniscalco, G.T.; Borriello, G.; De Luca, G.; Konrad, G.; Vaula, G.; Marfia, G.A.; Mallucci, G.; Liberatore, G.; Salemi, G.; Miele, G.; Sibilia, G.; Pesci, I.; Schiavetti, I.; Brambilla, L.; Lopiano, L.; Sinisi, L.; Pasquali, L.; Saraceno, L.; Carmisciano, L.; Chiveri, L.; Mancinelli, L.; Moiola, L.; Grimaldi, L.M.E.; Caniatti, L.M.; Capobianco, M.; Cava, M.D.; Onofrj, M.; Rovaris, M.; Salvetti, M.; Vercellino, M.; Bragadin, M.M.; Buccafusca, M.; Buscarinu, M.C.; Celani, M.G.; Grasso, M.G.; Stromillo, M.L.; Petracca, M.; Amato, M.P.; Sormani, M.P.; L’Episcopo, M.R.; Sessa, M.; Ferrò, M.T.; Trojano, M.; Ercolani, M.V.; Bianco, M.; Re, M.L.; Vianello, M.; Clerico, M.; Battaglia, M.A.; Napoli, M.; Ponzano, M.; Radaelli, M.; Conti, M.Z.; Calabrese, M.; Mirabella, M.; Filippi, M.; Inglese, M.; Lucchini, M.; Pozzato, M.; Danni, M.C.; Zaffaroni, M.; Zampolini, M.; Ponzio, M.; De Riz, M.; De Rossi, N.; De Stefano, N.; Cavalla, P.; De Mitri, P.; Grossi, P.; Zaratin, P.; Confalonieri, P.; Gallo, P.; Immovilli, P.; Ragonese, P.; Sola, P.; Annovazzi, P.; Iaffaldano, P.; Nardone, R.; Cerqua, R.; Clerici, R.; Lanzillo, R.; Motta, R.; Balgera, R.; Bergamaschi, R.; Totaro, R.; Iodice, R.; Capra, R.; Marangoni, S.; Realmuto, S.; Cottone, S.; Montepietra, S.; Rasia, S.; Arena, S.; Bucello, S.; Banfi, S.; Bonavita, S.; Malucchi, S.; Tonietti, S.; Vollaro, S.; Cordera, S.; Aguglia, U.; Clerici, V.T.; Barcella, V.; Bergamaschi, V.; Morra, V.B.; Dattola, V.; Mantero, V. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann. Neurol., 2021, 89(4), 780-789.
[http://dx.doi.org/10.1002/ana.26028] [PMID: 33480077]

Giovannoni, G. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. Mult. Scler. Relat. Disord., 2020, 41, 102135.
[http://dx.doi.org/10.1016/j.msard.2020.102135] [PMID: 32339915]

Hada, M.; Mosholder, A.D.; Leishear, K.; Perez-Vilar, S. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol. Sci., 2022, 43(3), 1557-1567.
[http://dx.doi.org/10.1007/s10072-021-05846-3] [PMID: 35006442]

Sharifian-Dorche, M.; Sahraian, M.A.; Fadda, G.; Osherov, M.; Sharifian-Dorche, A.; Karaminia, M.; Saveriano, A.W.; La Piana, R.; Antel, J.P.; Giacomini, P.S. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult. Scler. Relat. Disord., 2021, 50, 102800.
[http://dx.doi.org/10.1016/j.msard.2021.102800] [PMID: 33578206]

Baba, C.; Yigit, P.; Dastan, S.; Hancer, P.; Sagici, O.; Ozakbas, S.; Abasiyanik, Z. Challenges of persons with multiple sclerosis on ocrelizumab treatment during COVID-19 pandemic. Neurol. Clin. Neurosci., 2022, 10(1), 3-8.
[http://dx.doi.org/10.1111/ncn3.12561] [PMID: 34909197]

Silveira, C.; Guedes, R.; Maia, D.; Curral, R.; Coelho, R. Neuropsychiatric symptoms of multiple sclerosis: State of the art. Psychiatry Investig., 2019, 16(12), 877-888.
[http://dx.doi.org/10.30773/pi.2019.0106] [PMID: 31805761]

Available from:https://www.aifa.gov.it/sites/default/files/Ocrevus.pdf

Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; Fujihara, K.; Galetta, S.L.; Hartung, H.P.; Kappos, L.; Lublin, F.D.; Marrie, R.A.; Miller, A.E.; Miller, D.H.; Montalban, X.; Mowry, E.M.; Sorensen, P.S.; Tintoré, M.; Traboulsee, A.L.; Trojano, M.; Uitdehaag, B.M.J.; Vukusic, S.; Waubant, E.; Weinshenker, B.G.; Reingold, S.C.; Cohen, J.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol., 2018, 17(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(17)30470-2] [PMID: 29275977]

Available from:https://www.neurostatus.net/

Available from:https://www.salute.gov.it/portale/nuovocorona-virus/dettaglioFaqNuovoCoronavirus.jsp?lingua=english&id=230

Sahi, N.K.; Abidi, S.M.A.; Salim, O.; Abraham, R.; Kalra, S.; Al-Araji, A. Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation. Mult. Scler. Relat. Disord., 2021, 56, 103287.
[http://dx.doi.org/10.1016/j.msard.2021.103287] [PMID: 34627005]

van Lierop, Z.Y.G.J.; Toorop, A.A.; van Ballegoij, W.J.C.; Olde Dubbelink, T.B.G.; Strijbis, E.M.M.; de Jong, B.A.; van Oosten, B.W.; Moraal, B.; Teunissen, C.E.; Uitdehaag, B.M.J.; Killestein, J.; Kempen, Z.L.E. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult. Scler., 2022, 28(7), 1121-1125.
[http://dx.doi.org/10.1177/13524585211028833] [PMID: 34240631]

Zanghì, A.; Avolio, C.; Signoriello, E.; Abbadessa, G.; Cellerino, M.; Ferraro, D.; Messina, C.; Barone, S.; Callari, G.; Tsantes, E.; Sola, P.; Valentino, P.; Granella, F.; Patti, F.; Lus, G.; Bonavita, S.; Inglese, M.; D’Amico, E. Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? evidence from an italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics, 2022, 19(5), 1535-1545.
[http://dx.doi.org/10.1007/s13311-022-01289-6] [PMID: 36036858]

Montalban, X.; Hauser, S.L.; Kappos, L.; Arnold, D.L.; Bar-Or, A.; Comi, G.; de Seze, J.; Giovannoni, G.; Hartung, H.P.; Hemmer, B.; Lublin, F.; Rammohan, K.W.; Selmaj, K.; Traboulsee, A.; Sauter, A.; Masterman, D.; Fontoura, P.; Belachew, S.; Garren, H.; Mairon, N.; Chin, P.; Wolinsky, J.S. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med., 2017, 376(3), 209-220.
[http://dx.doi.org/10.1056/NEJMoa1606468] [PMID: 28002688]

D’Amico, E.; Patti, F.; Zanghì, A.; Zappia, M. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int. J. Mol. Sci., 2016, 17(10), 1725.
[http://dx.doi.org/10.3390/ijms17101725] [PMID: 27763513]

Zanghì, A.; D’Amico, E.; Luca, M.; Ciaorella, M.; Basile, L.; Patti, F. Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Mult. Scler. Relat. Disord., 2020, 46, 102561.
[http://dx.doi.org/10.1016/j.msard.2020.102561] [PMID: 33045494]

van Kempen, Z.L.E.; Hoogervorst, E.L.J.; Wattjes, M.P.; Kalkers, N.F.; Mostert, J.P.; Lissenberg-Witte, B.I. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology, 2020, 95(6), e745-e754.
[http://dx.doi.org/10.1212/WNL.0000000000009995] [PMID: 32690785]

Ellrichmann, G.; Bolz, J.; Peschke, M.; Duscha, A.; Hellwig, K.; Lee, D.H.; Linker, R.A.; Gold, R.; Haghikia, A. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J. Neurol., 2019, 266(1), 57-67.
[http://dx.doi.org/10.1007/s00415-018-9092-4] [PMID: 30377816]

Benkert, P.; Meier, S.; Schaedelin, S.; Manouchehrinia, A.; Yaldizli, Ö.; Maceski, A.; Oechtering, J.; Achtnichts, L.; Conen, D.; Derfuss, T.; Lalive, P.H.; Mueller, C.; Müller, S.; Naegelin, Y.; Oksenberg, J.R.; Pot, C.; Salmen, A.; Willemse, E.; Kockum, I.; Blennow, K.; Zetterberg, H.; Gobbi, C.; Kappos, L.; Wiendl, H.; Berger, K.; Sormani, M.P.; Granziera, C.; Piehl, F.; Leppert, D.; Kuhle, J.; Aeschbacher, S.; Barakovic, M.; Buser, A.; Chan, A.; Disanto, G.; D’Souza, M.; Du Pasquier, R.; Findling, O.; Galbusera, R.; Hrusovsky, K.; Khalil, M.; Lorscheider, J.; Mathias, A.; Orleth, A.; Radue, E-W.; Rahmanzadeh, R.; Sinnecker, T.; Subramaniam, S.; Vehoff, J.; Wellmann, S.; Wuerfel, J.; Zecca, C. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol., 2022, 21(3), 246-257.
[http://dx.doi.org/10.1016/S1474-4422(22)00009-6] [PMID: 35182510]